Press Release: AIRA Matrix, Lumea, and Acupath Have Partnered to Provide a Diagnostic AI Solution for the URO17® Bladder Cancer Biomarker
admin@pathologynews.com2025-06-06T10:16:47+00:00AIRAMatrix Private Limited, is an innovative technology company for AI-based diagnostic, prognostic, and predictive applications in cancer care. Acupath is a leading provider of sub-specialized anatomic and molecular pathology services. Lumea is a leader in digital pathology solutions. These companies have joined forces to deliver an AI-based solution to assist in the diagnosis of urinary bladder cancers through cytopathological examination.










